B-spectrin (SPTBN1) deficiency protects mice from high-fat diet-induced liver disease and cancer progression

JP2023549505A5Pending Publication Date: 2024-11-20GEORGE WASHINGTON UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528428
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-02-08
Filing Date
2021-11-12
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Current treatments for non-alcohol-related fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) are limited in effectively reversing fibrosis and steatosis, and there is a need for new approaches targeting the molecular mechanisms underlying these conditions, particularly those involving aberrant lipid accumulation and fibrosis progression.

Method used

Administering a therapeutically effective amount of siRNA molecules that inhibit the expression of SPTBN1, a protein involved in regulating caspase-3-induced SREBP activity, to reduce profibrotic gene expression and nascent lipid biosynthesis, thereby protecting against obesity, NAFLD, and HCC.

Benefits of technology

The method effectively prevents obesity, reduces liver damage, and inhibits the progression to NAFLD and HCC by decreasing lipid accumulation and fibrosis, as demonstrated in both mouse models and human cell cultures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, the method comprising administering a therapeutically effective amount of at least one siRNA molecule targeting SPTBN1. At least one of the siRNA molecules that inhibit SPTBN1 expression comprises 15 to 30 nucleotides. At least one of the siRNA molecules that inhibit SPTBN1 expression comprises an overhang region of 1 to 6 nucleotides.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Government support This invention was made with government support under U01 CA230690 and R01 M023146, as recognized by the National Institutes of Health. The government has certain rights in this invention.

[0002] Reference to electronically submitted sequence listings The entire contents of the sequence listing submitted electronically with this application in an ASCII text file (name: 3973_018PC02_Seqlisting_ST25.txt, size: 37,736 bytes, creation date: November 3, 2021) are incorporated herein by reference.

[0003] This disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a person in need thereof, the method comprising administering a therapeutically effective dose of an SPTBN1-targeting siRNA molecule. [Background technology]

[0004] Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are caused by obesity and metabolic disorders and affect one-third of the world's population (1,2). These diseases encompass a range of factors including lipid accumulation (steatosis), damage, inflammation, ballooning degeneration (cell death) of hepatocytes, and progressive fibrosis (cirrhosis) in the liver, ultimately leading to cancer (3,4). Lipid accumulation in the liver promotes chronic oxidative and endoplasmic reticulum (ER) stress, cell death, immune cell inflammation, fibrosis, and disease progression. These effects are exacerbated by factors such as increased free fatty acid (FFA) uptake, a sedentary lifestyle, and hyperinsulinemia. Depending on whether NASH is accompanied by cirrhosis, the incidence of liver cancer can range from 2.4% (without cirrhosis) to 12.8% (with cirrhosis) (1,3). Obesity doubles the risk of liver cancer mortality and, together with NASH, contributes to the significant increase in this cancer (5,6). Despite the existence of new therapeutic approaches targeting NASH, there are few monotherapies that reverse both fibrosis and steatosis, making NASH a major clinical challenge (5,7). Therefore, understanding the molecular mechanisms that converge on abnormal lipid accumulation, fibrosis, and the fatal transformation to hepatocellular carcinogenesis could lead to new approaches targeting NASH in specific groups prone to disease progression.

[0005] The development of NAFLD is thought to be accompanied by the abnormal accumulation of free fatty acids, triglycerides, and cholesterol, along with neolipid biosynthesis. Activation of the hepatocyte death receptor pathway, tumor necrosis factor (TNF), and caspases contributes to the tissue damage and steatohepatitis seen in NASH (8,9). Neolipid biosynthesis is stimulated by the activation of the transcription factor sterol regulatory element (SRE) binding protein (SREBP) and the suppression of energy-sensing pathways, such as those involving adenosine monophosphate (AMP)-activated protein kinase (AMPK). SREBP1 is the dominant lipid biosynthesis transcription factor that promotes fatty acid synthesis and contributes to steatosis (10). The SREBP protein is maintained within the endoplasmic reticulum through interactions with the proteins INSIG and SCAP. For SREBP to be activated in response to sterol depletion or ER stress, INSIG dissociation and SCAP-induced cleavage of SREBP by site-1 protease (S1P) followed by a second cleavage by site-2 protease (S2P) are necessary to generate a mature form of SREBP protein that translocates into the nucleus and regulates target gene transcription (11). In cultured cells under stress, SREBP1 and SREBP2 are cleaved and activated by caspase-3 in the presence of activated caspase-3, but the physiological context of this is unknown (12). The cleaved nuclear form is called n-SREBP, and the full-length ER-localized form is called precursor SREBP.

[0006] The degree of fibrosis is considered the strongest predictor of progression from NALFD to NASH and ultimately to hepatocellular carcinoma (HCC) (1,13,14). Crucial to liver fibrosis is the activation of the transforming growth factor β (TGF-β) pathway (15,16). TGF-β1 is a founding member of this family, and its ligand signals via two serine-threonine kinase receptors (TGFBR2 and TGFBR1) that activate SMAD transcription regulators. The SMAD complex, containing SMAD3, plays a central role in the progression of fibrosis by causing overexpression of extracellular matrix genes such as those encoding collagen COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, and COL6A3, as well as by stimulating genes encoding protease inhibitors, tissue metalloproteinase inhibitors (TIMP), and plasminogen activator inhibitor 1 (PAI-1) (16). The SMAD3 complex also represses the gene encoding peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-α) (17). The SMAD3-mediated pro-fibrotic effect of TGF-β1 involves multiple mechanisms and cell types, including enhanced infiltration and proliferation (or both) of tissue-resident fibroblasts, myofibroblast generation, induction of epithelial-mesenchymal transition (EMT), and inhibition of collagen lysis (18).

[0007] SPTBN1 (also known as β2-spectrin or β2SP) is a multi-domain adapter protein with functions in the cytoplasm and nucleus (19-21). Specifically, SPTBN1 promotes TGF-β receptor activation of SMAD3 in the cytosol (22) and interacts with SMAD3 in the nucleus to regulate specific target genes (23,24). SPTBN1 is a dynamic tetrameric protein consisting of two antiparallel dimers, alpha and beta subunits. SPTBN1 binding partners include ankyrin, which functions to link proteins in the cell membrane to the spectrin-containing cytoskeleton, and lamin and the chromatin regulator CTCF (CCCTC binding factor), which function to organize chromatin and regulate gene expression in the nucleus (19,23,25,26). SPTBN1 is a substrate of caspases 3 and 7, and the SPTBN1 1454DEVD1457 peptide sequence generates two distinct fragments (160 and 80 kDa) with different functions in apoptosis and transcription (27). The importance of SPTBN1 in liver disease stems from the finding that mice treated with shRNA targeting SPTBN1 exhibit less acetaminophen-induced hepatotoxicity (27). Increased levels of hepatic SMAD3 and SPTBN1, as well as TGF-β pathway members associated with the fibrosis-promoting pathway, were observed in approximately 40% of HCC cases, and many HCCs are linked to NASH (24,28). [Brief explanation of the drawing]

[0008] [Figure 1A] none. [Figure 1B] none. [Figure 1C] none. [Figure 1D] none. [Figure 1E] none. [Figure 1F] none. [Figure 1G] none. [Figure 2A] none. [Figure 2B] none. [Figure 2C] None. [Figure 2D] None. [Figure 2E] None. [Figure 2F] None. [Figure 2G] None. [Figure 2H] None. [Figure 3A] None. [Figure 3B] None. [Figure 3C] None. [Figure 3D] None. [Figure 3E] None. [Figure 3F] None. [Figure 4A] None. [Figure 4B] None. [Figure 4C] None. [Figure 4D] None. [Figure 4E] None. [Figure 4F] None. [Figure 4G] None. [Figure 5A] None. [[ID=X]] [Figure 5B] None. [Figure 5C] None. [Figure 5D] None. [Figure 5E] None. [Figure 5F] None. [Figure 6A] None. [Figure 6B] None. [Figure 6C] None. [[ID=X]] [Figure 6D] None. [Figure 6E] None. [Figure 6F] None. [Figure 6G] None. [Figure 6H] None. [Figure 6I] None. [Figure 6J] None. [Figure 7A] none. [Figure 7B] none. [Figure 7C] none. [Figure 7D] none. [Figure 7E] none. [Figure 7F] none. [Figure S1A] none. [Figure S1B] none. [Figure S1C] none. [Figure S1D] none. [Figure S1E] none. [Figure S1F] none. [Figure S1G] none. [Figure S1H] none. [Figure S2A] none. [Figure S2B] none. [Figure S2C] none. [Figure S2D] none. [Figure S2E] none. [Figure S3A] none. [Figure S3B] none. [Figure S3C] none. [Figure S4A] none. [Figure S4B] none. [Figure S4C] none. [Figure S4D] none. [Figure S4E] none. [Figure S5A] none. [Figure S5B] none. [Overview of the Initiative] [Means for solving the problem]

[0009] This disclosure provides a method for treating a disease, disorder, or medical condition, such as obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma, in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits SPTBN1 expression. [Modes for carrying out the invention]

[0010] The role of SPTBN1 in hepatic tumorigenesis was studied by creating liver-specific SPTBN1 conditional knockout (LSKO) mice. LSKO mice, or mice treated with SPTBN1-targeted siRNA, were shown to be protected from the adverse effects of a high-fat diet through a mechanism involving reduced expression of pro-fibrosis genes and genes involved in nascent lipid biosynthesis. The mice did not become obese or progress to NASH or HCC. The translational significance of the results was supported by analysis of SPTBN1 expression in human NASH and HCC, and by the finding that SPTBN1-targeted siRNA reversed transcriptional changes in genes involved in fatty acid metabolism and fibrosis induced in a human three-dimensional culture model of NASH. Thus, the results revealed a previously unknown role of SPTBN1 in regulating caspase-3-induced SREBP activity in response to stress conditions induced by a high-fat diet (HFD).

[0011] In one embodiment, the present disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits SPTBN1 expression.

[0012] In another embodiment, at least one siRNA molecule that inhibits SPTBN1 expression contains 15 to 30 nucleotides.

[0013] In another embodiment, at least one siRNA molecule that inhibits SPTBN1 expression contains 15 to 20 nucleotides.

[0014] In another embodiment, at least one of the siRNA molecules that inhibit SPTBN1 expression includes an overhang region of 1 to 6 nucleotides.

[0015] In another embodiment, at least one of the siRNA molecules that inhibit SPTBN1 expression does not contain an overhang region.

[0016] In another embodiment, at least one siRNA molecule that inhibits SPTBN1 expression is shown as SEQ ID NO: 7.

[0017] In another embodiment, at least one siRNA molecule that inhibits SPTBN1 expression is shown as SEQ ID NO: 8.

[0018] In another embodiment, at least one siRNA molecule that inhibits SPTBN1 expression is shown as SEQ ID NO: 9.

[0019] In another embodiment, at least one siRNA molecule that inhibits SPTBN1 expression is shown as SEQ ID NO: 10.

[0020] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 is homologous to at least 10 nucleotides of SEQ ID NO: 7. In another embodiment, at least one of the siRNA molecules that inhibits the expression of SPTBN1 is homologous to at least 15 nucleotides of SEQ ID NO: 7.

[0021] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits SPTBN1 expression, wherein at least one of the siRNA molecules that inhibits SPTBN1 expression is homologous to at least 10 nucleotides of SEQ ID NO: 8. In another embodiment, at least one of the siRNA molecules that inhibits SPTBN1 expression is homologous to at least 15 nucleotides of SEQ ID NO: 8.

[0022] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 is homologous to at least 10 nucleotides of SEQ ID NO: 9. In another embodiment, at least one of the siRNA molecules that inhibits the expression of SPTBN1 is homologous to at least 15 nucleotides of SEQ ID NO: 9.

[0023] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 is homologous to at least 10 nucleotides of SEQ ID NO: 10. In another embodiment, at least one of the siRNA molecules that inhibits the expression of SPTBN1 is homologous to at least 15 nucleotides of SEQ ID NO: 10.

[0024] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective dose of at least one siRNA molecule that inhibits SPTBN1 expression, wherein at least one of the siRNA molecules that inhibits SPTBN1 expression has at least 90% sequence identity with SEQ ID NO: 7. In another embodiment, at least one of the siRNA molecules that inhibits SPTBN1 expression has at least 95% sequence identity with SEQ ID NO: 7.

[0025] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 has at least 90% sequence identity with SEQ ID NO: 8. In another embodiment, at least one of the siRNA molecules that inhibits the expression of SPTBN1 has at least 95% sequence identity with SEQ ID NO: 8.

[0026] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective amount of at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 has at least 90% sequence identity with SEQ ID NO: 9. In another embodiment, at least one of the siRNA molecules that inhibits the expression of SPTBN1 has at least 95% sequence identity with SEQ ID NO: 9.

[0027] In another embodiment, the Disclosure provides a method for treating obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma in a subject in need thereof, comprising administering a therapeutically effective dose of at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 has at least 90% sequence identity with SEQ ID NO: 10. In another embodiment, at least one of the siRNA molecules that inhibits the expression of SPTBN1 has at least 95% sequence identity with SEQ ID NO: 10.

[0028] In another embodiment, the Disclosure provides a method for treating obesity in a subject in need thereof. In another embodiment, treating obesity includes reducing the amount of body fat in the subject and / or reducing the subject's weight.

[0029] In another embodiment, the Disclosure provides a method for treating non-alcohol-related fatty liver disease in a subject in need of such treatment. In another embodiment, treating non-alcohol-related fatty liver disease includes reducing blood triglycerides in the subject.

[0030] In another embodiment, the Disclosure provides a method for treating non-alcoholic steatohepatitis in a subject in need of such treatment. In another embodiment, treating non-alcoholic steatohepatitis includes reducing blood triglycerides in the subject.

[0031] In another embodiment, the Disclosure provides a method for treating hepatocellular carcinoma in a subject in need of such treatment. In another embodiment, treating hepatocellular carcinoma includes reducing the tumor mass in the subject.

[0032] In another embodiment, 1 to 10 siRNA molecules that inhibit SPTBN1 expression, for example, 1 to 5 siRNA molecules, for example, 1 to 3 siRNA molecules are administered. In another embodiment, 1 siRNA molecule that inhibits SPTBN1 expression is administered. In another embodiment, 2 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 3 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 4 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 5 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 6 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 7 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 8 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 9 siRNA molecules that inhibit SPTBN1 expression are administered. In another embodiment, 10 siRNA molecules that inhibit SPTBN1 expression are administered.

[0033] The terms “to treat,” “to treat,” “treatment,” and similar terms are used herein to mean eliminating, reducing, or improving a disease or condition and / or symptoms associated therewith. Treating a disease or condition does not preclude, but does not require, the complete elimination of the disease, condition or symptoms associated therewith.

[0034] As used herein, the term "therapeutic effective dose" refers to an amount of a therapeutic agent, such as an siRNA molecule that inhibits the expression of SPTBN1, that is sufficient to improve one or more symptoms of the disorder, prevent its progression, or cause regression of the disorder. For example, with respect to cancer treatment, in one embodiment, the therapeutically effective dose would refer to the amount of a therapeutic agent that produces a therapeutic response, such as normalization of blood counts, a decrease in the rate of tumor growth, a decrease in tumor mass, a decrease in the number of metastases, an increase in the time required for tumor progression, and / or increases the target survival by at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% or more. With regard to the treatment of obesity, in one embodiment, a therapeutically effective dose refers to the amount of a therapeutic agent that causes a reduction of at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% or more of body fat or body weight in the subject.With regard to the treatment of NAFLD or NASH, in one embodiment, a therapeutically effective dose refers to the amount of therapeutic agent that causes a reduction of at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% or more of blood triglycerides in the subject.

[0035] The terms “G,” “C,” “A,” “T,” and “U” generally refer to naturally occurring nucleotides containing guanine, cytosine, adenine, thymidine, and uracil as bases, respectively. However, it will be understood that the term “nucleotide” also refers to alternative nucleotides or alternative substitutions, which are further detailed below. Those skilled in the art will be well aware that substituting guanine, cytosine, adenine, and uracil with other parts can be done without substantially altering the base-pairing properties of the oligonucleotide containing the nucleotide having such substitution. For example, but not limited to, a nucleotide containing inosine as a base can base-pair with adenine, cytosine, or uracil. Therefore, a nucleotide containing uracil, guanine, or adenine can be replaced, for example, with an inosine-containing nucleotide in the nucleotide sequence of the dsRNA characterized in this invention. In another example, adenine and cytosine at any location in an oligonucleotide can be replaced with guanine and uracil, respectively, to form a GU Wobble base pair with a target mRNA sequence. Sequences containing such substitution portions are suitable for the compositions and methods characterized by the present invention.

[0036] The terms “nucleic acid base” and “base” include purine (e.g., adenine and guanine) and pyrimidine (e.g., uracil, thymine, and cytosine) moieties present in nucleosides and nucleotides that form hydrogen bonds in nucleic acid hybridization. In the context of this invention, the term nucleic acid base also includes alternative nucleic acid bases that may differ from naturally occurring nucleic acid bases but are functional during nucleic acid hybridization. In this context, “nucleic acid base” refers to both naturally occurring nucleic acid bases, e.g., adenine, guanine, cytosine, thymine, uracil, xanthine, and hypoxanthine, as well as alternative nucleic acid bases. Such variants are described, for example, in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.

[0037] The term "nucleoside" refers to a monomeric unit of an oligonucleotide or polynucleotide having a nucleic acid base and a sugar moiety. Nucleosides may include naturally occurring ones and alternative nucleosides, such as those described herein. The nucleic acid base of a nucleoside may be a naturally occurring nucleic acid base or an alternative nucleic acid base. Similarly, the sugar moiety of a nucleoside may be a naturally occurring sugar or an alternative sugar.

[0038] The term "alternative nucleoside" refers to a nucleoside having an alternative sugar or alternative nucleic acid base, such as those described herein.

[0039] In some embodiments, the nucleic acid base moiety is modified by replacing the purine or pyrimidine with an "alternative nucleic acid base" selected from modified purines or pyrimidines, such as substituted purines or pyrimidines, for example, isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiozolo-cytosine, 5-propynylcytosine, 5-propynyluridine, 5-bromouridine, 5-thiazolouridine, 2-thiouridine, pseudouridine, 1-methylpseudridine, 5-methoxyuridine, 2'-thiothymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine.

[0040] The nucleic acid base portion may be represented by a letter symbol for each corresponding nucleic acid base, for example, A, T, G, C, or U, and each letter may optionally contain an alternative nucleic acid base having an equivalent function.

[0041] The term "sugar" or "sugar moiety" includes naturally occurring sugars that have a furanose ring. Sugars also include "alternative sugars," defined as structures that can replace the furanose ring in a nucleoside. In certain embodiments, alternative sugars are non-furanose (or 4'-substituted furanose) rings or ring systems, or ring-open systems. Such structures may involve simpler modifications compared to the natural furanose ring, such as a six-membered ring, or they may be more complex, as in the case of acyclic systems used in peptide nucleic acids. Alternative sugars may also include sugar substitutes in which the furanose ring is replaced by another ring system, such as a morpholino or hexitol ring system. Useful sugar moieties in the preparation of oligonucleotides with motifs include, but are not limited to, β-D-ribose, β-D-2'-deoxyribose, substituted sugars (e.g., 2', 5', and disubstituted sugars), 4'-S-sugars (e.g., 4'-S-ribose, 4'-S-2'-deoxyribose, and 4'-S-2'-substituted ribose), bicyclic alternative sugars (e.g., bicyclic sugars derived from 2'-O-CH2-4'- or 2'-O-(CH2)2-4'-bridged ribose), and sugar substitutes (e.g., when the ribose ring is replaced with a morpholino or hexitol ring system). The type of heterocyclic base and nucleoside linkage used at each position is indeterminate and is not a factor in determining the motif. In most nucleosides with alternative sugar moieties, the heterocyclic nucleic acid bases are generally maintained to allow hybridization.

[0042] As used herein, “nucleotide” refers to a monomeric unit of an oligonucleotide or polynucleotide comprising a nucleoside and an internucleoside linkage. The internucleoside linkage may or may not include a phosphate linkage. Similarly, “linked nucleosides” may or may not be linked by a phosphate linkage. Many “alternative internucleoside linkages” are known in the art, including but not limited to phosphate, phosphorothioate, and voronophosphate linkages. Alternative nucleosides include bicyclic nucleosides (BNAs) (e.g., locked nucleosides (LNAs) and restricted ethyl (cEt) nucleosides), peptide nucleosides (PNAs), phosphotriesters, phosphorothionates, phosphoramidates, and other variants of the phosphate backbone of natural nucleosides, including those described herein.

[0043] "Alternative nucleotide," as used herein, means a nucleotide having an internucleoside linkage which may include an alternative nucleoside or alternative sugar and an alternative nucleoside linkage.

[0044] The terms “oligonucleotide” and “polynucleotide,” as used herein, are defined as those commonly understood by those skilled in the art, as molecules comprising two or more covalently linked nucleosides. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are often produced in the laboratory by solid-phase chemical synthesis and subsequent purification. When referring to the sequence of an oligonucleotide, the reference is to the sequence or order of the nucleic acid base portion of the covalently linked nucleotide or nucleoside, or its variants. The oligonucleotides of the present invention may be artificial, chemically synthesized, and typically purified or isolated. Oligonucleotides are also intended to include (i) compounds having one or more furanose moieties replaced with a furanose derivative or any cyclic or acyclic structure that can be used as a covalent bonding site to a base moiety; (ii) compounds having one or more phosphorodiester linkages that are either modified, as in the case of phosphoramidate or phosphorothioate linkages, or completely replaced with a suitable linking moiety, as in the case of formacetal or riboacetal linkages; and / or (iii) compounds having one or more bonded furanose-phosphodiester linkage moieties replaced with any cyclic or acyclic structure that can be used as a covalent bonding site to a base moiety. Oligonucleotides of the present invention may include one or more alternative nucleosides or nucleotides (e.g., those described herein). It is also understood that oligonucleotides may include synthetic compounds that lack a sugar moiety or nucleic acid base but can still form base pairings or hybridize with a target sequence.

[0045] "Oligononucleotide" refers to a short polynucleotide (for example, a polynucleotide consisting of 100 or fewer bonded nucleosides).

[0046] As used herein, the term “chain” refers to an oligonucleotide containing a chain of bound nucleosides. “Nucleic acid sequence-containing chain” refers to an oligonucleotide containing a chain of bound nucleosides described by a sequence referred to using standard nucleic acid nomenclature.

[0047] The term “antisense,” as used herein, refers to nucleic acids containing oligonucleotides or polynucleotides that are sufficiently complementary to all or part of a gene, primary transcript, or processed mRNA in order to interfere with the expression of an endogenous gene (e.g., MLH3). “Complementary” polynucleotides are those that can base-pair according to the standard Watson-Crick complementarity rules. Specifically, purines will base-pair with pyrimidines to form guanine (G:C) compound paired with cytosine, and adenine compound paired with either thymine (A:T) in the case of DNA or uracil (A:U) in the case of RNA. It is understood that two polynucleotides can hybridize with each other, provided that each has at least one region that is substantially complementary to the other, even if they are not perfectly complementary to each other.

[0048] The terms "antisense strand" and "guide strand" refer to strands of dsRNA that contain a region substantially complementary to the target sequence, such as MLH3 mRNA.

[0049] When used herein, the terms “sense strand” and “passenger strand” refer to a strand of dsRNA that contains a region substantially complementary to the antisense strand region for which the terms are defined herein.

[0050] The term "dsRNA" refers to a drug comprising sense and antisense strands containing the binding nucleoside defined herein. Examples of dsRNAs include siRNA and shRNA, which mediate targeted cleavage of RNA transcripts via the RNA-induced silencing complex (RISC) pathway. dsRNAs induce sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). dsRNAs reduce MLH3 expression in cells, such as those in mammalian subjects. Generally, most of the binding nucleosides on each strand of dsRNA are ribonucleosides, but as described in detail herein, one or both strands may also contain one or more non-ribonucleosides, such as deoxyribonucleosides and / or alternative nucleosides.

[0051] The terms "siRNA" and "short interfering RNA" (also known as "small interfering RNA") refer to RNA agents, preferably double-stranded agents, that are about 10 to 50 nucleotides long, and which may have overhang ends containing, for example, one, two, or three overhang-binding nucleosides, and which can induce or mediate RNA interference. Naturally occurring siRNAs are produced by the cellular RNAi mechanism (e.g., Dicer or its homologs) from longer (e.g., longer than 25-binding nucleosides) dsRNA molecules.

[0052] As used herein, the terms "shRNA" and "short hairpin RNA" refer to RNA preparations having a stem-loop structure, comprising first and second regions of complementary sequences, wherein the degree of complementarity and orientation of these regions is satisfactory to allow base pairing between them, and the first and second regions are joined by a loop region, the loop being obtained by the absence of base pairing between nucleic acid bases within the loop region.

[0053] In the context of the present invention, "chimeric" dsRNA or "chimera" is a dsRNA that contains at least one monomeric unit, i.e., two or more chemically distinct regions, each composed of a nucleoside or nucleotide in the case of dsRNA.

[0054] The double-stranded region can be of any length that allows for the specific degradation of the desired target RNA via the RISC pathway, ranging in length from approximately 9 to 36 base pairs, for example, approximately 10 to 30 base pairs, for example, approximately 15 to 30 base pairs, or approximately 18 to 20 base pairs, for example, approximately 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs, for example, approximately 15 to 30, 15 to 29, 15 to 28, 15 to 27, 15 to 26, 15 to 25, 15 to 24, 15 to 23, 15 to 22, 15 to 21, 15 to 20 , 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, The lengths may be 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Ranges and lengths intermediate between the above-listed ranges and lengths are also intended to be part of the present invention.

[0055] The two strands forming a double helix structure may be different parts of a single longer oligonucleotide molecule, or they may be separate oligonucleotide molecules. If the two strands are parts of a single larger molecule and are therefore linked by an uninterrupted chain of binding nucleosides between the 3' end of one strand forming the double helix structure and the 5' end of each of the other strands, the linking strands are referred to as a “hairpin loop.” A hairpin loop may contain at least one unpaired nucleic acid base. In some embodiments, a hairpin loop may contain at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least twenty, at least 23, or more unpaired nucleic acid bases. In some embodiments, a hairpin loop may contain 10 or fewer binding nucleosides. In some embodiments, a hairpin loop may contain 8 or fewer unpaired nucleic acid bases. In some embodiments, a hairpin loop may contain 4 to 10 unpaired nucleic acid bases. In some embodiments, the hairpin loop may consist of 4 to 8 bonded nucleosides.

[0056] In one embodiment, each strand of dsRNA contains 19–23 binding nucleosides that interact with a target RNA sequence, such as an MLH3 target mRNA sequence, to induce cleavage of the target RNA. Without dwelling on theory, long double-stranded RNA introduced into cells is degraded by a type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease III-like enzyme, processes RNA into short interfering RNAs of 19–23 base pairs with a characteristic double 3' overhang (Bernstein, et al., (2001) Nature 409:363). The dsRNA is then unwound by one or more helicases into the RNA-induced silencing complex (RISC), which is the site where the complementary antisense strand guides target recognition (Nykanen, et al., (2001) Cell 107:309). As soon as binding to the appropriate target mRNA occurs, one or more endonucleases within the RISC cleave the target and induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188). The two substantially complementary strands of the dsRNA are composed of distinct RNA molecules, which can, but not necessarily, be covalently linked. When the two strands are covalently linked by means other than an unbroken chain of nucleotides between the 3' end of one strand forming the double-stranded structure and the 5' end of each of the other strands, the linking structure is called a "linker".

[0057] The term “linker” or “linking group” refers to an organic portion that links two parts of a compound, for example, covalently bonded to two parts of a compound. RNA strands may have the same or different number of bound nucleosides. The maximum number of base pairs is the number of bound nucleosides in the shortest strand of dsRNA minus any overhangs present in the double helix. In addition to the double helix structure, dsRNA may contain one or more nucleoside overhangs. In one embodiment of dsRNA, at least one strand contains a 3' overhang of at least one nucleoside. In another embodiment, at least one strand contains a 3' overhang of at least two bound nucleosides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 bound nucleosides. In yet another embodiment, at least one strand of dsRNA contains a 5' overhang of at least one nucleoside. In certain embodiments, at least one strand includes a 5' overhang of at least two-binding nucleosides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15-binding nucleosides. In yet another embodiment, both the 3' and 5' ends of one strand of dsRNA include an overhang of at least one nucleoside.

[0058] A linker or tether also refers to a two-atom linkage that connects one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds. The conjugate portion may be bound to dsRNA directly or via a tether (e.g., a linker or tether). The linker plays a role in covalently linking a third region, e.g., the conjugate portion, to the dsRNA (e.g., terminal A or C of the region). In some embodiments of the present invention, the conjugate or dsRNA conjugate of the present invention may optionally include a linker region positioned between the dsRNA and the conjugate portion. In some embodiments, the linker between the conjugate and the dsRNA is biologically cleavable. Biologically cleavable linkers containing phosphodiesters are described in detail in WO2014 / 076195 (incorporated herein by reference).

[0059] As used herein, the term “nucleoside overhang” refers to at least one unpaired nucleoside base protruding from the double-stranded structure of a dsRNA or siRNA. For example, a nucleoside overhang exists when the 3' end of one strand of a dsRNA extends beyond the 5' end of the other strand, or vice versa. A dsRNA may contain an overhang of at least one nucleoside, or the overhang may contain at least two, at least three, at least four, at least five, or more nucleosides. A nucleoside overhang may contain or consist of alternative nucleosides, including deoxynucleotides / nucleosides. Overhangs may reside on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleosides of an overhang may reside on the 5' end, the 3' end, or both ends of either the antisense or sense strand of the dsRNA. In certain embodiments, the overhang includes a self-complementary portion such that the overhang can form a stable hairpin structure under physiological conditions.

[0060] The terms "a" and "an" mean one or more. [Examples]

[0061] General methods and sequence listings Details of the experimental model and subjects Study population (patients with NASH) The Cambridge cohort consisted of a series of 58 NAFLD patients (NAFL: 19, NASH F0-2: 24, NASH F3-4: 15) recruited at the NASH Department of Cambridge University Hospital. All patients had a clinically and biopsy-proven diagnosis of NAFLD (patients with alternative diagnoses due to different etiologies and those with fatty liver were excluded), histology recorded by a trained human pathologist according to the NASH CRN scoring system (NAS1), and flash-frozen tissue for research purposes (gene expression by next-generation sequencing, see below). All comparisons were made against the NAFLD group. This study was approved by the local ethics committee and adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from all patients regarding the use of their clinical / omics data and samples for research purposes. Detailed patient information for NASH / HCC patients from single-cell sequencing from UCLA is provided in Table 1. [Table 1]

[0062] Mouse strain, HFD feeding, and DEN injection All animal experiments were conducted in accordance with guidelines for the management and use of laboratory animals and were approved by the Biomedical Research Ethics Committee for Biomedical Research at George Washington University. C57BL / 6 mice were purchased from Jackson Laboratories and manipulated. Male and female mice were used in our experiments. To induce liver-specific deletion in Sptbn1 mice, Flox sites were inserted along with Neo cassettes on both sides of exons 24-26 of the Sptbn1 gene. Subsequently, the Neo cassettes were removed by crossing with Flp mice. Then, Sptbn1-Flox mice were crossed with albumin-Cre to induce liver-specific deletion in Sptbn1 mice. For high-fat diet (HFD)-induced hepatic steatosis, 10-12 week old male and female mice were fed either a control diet or HFD (ENVIGO, Cat.TD.06414) for 12-20 weeks. Blood glucose, triglyceride (TG), and cholesterol levels were measured using a blood glucose meter, CardioChek PA analyzer, and PTS Panels lipid panel test strips. For a DEN-induced liver cancer model, 25 mg / kg of DEN was injected into 14-15 day-old male and female mice. Tumor progression was analyzed after 6-10 months. Liver and visceral adipose tissue were dissected and weighed. Spleen, heart, brain, muscle, and brown adipose tissue were also collected for further histological analysis.

[0063] Generation of cell lines and cell cultures Sptbn1 - / - ,Sptbn1 + / -WT MEF cells were generated from Sptbn1 cross mice. Human liver cancer cell lines Hep3B, HepG2, and Huh7, as well as the mouse immortalized hepatocyte cell line AML12, were purchased from ATCC and cultured in complete culture medium DMEM / F12 (Corning, Cat.10-090-CV) supplemented with 1% streptomycin-penicillin and 10% FBS (Hyclone, Cat.SH30396.03). Human immortalized hepatocyte cell line THLE2, purchased from ATCC, was cultured in BEGM medium (Lonza / Clonetics Corporation, Cat.CC3170) supplemented with BPE (bovine pituitary extract), hydrocortisone, hEGF, insulin, triiodothyronine, transferrin, and retinoic acid from the BEGM culture medium kit (Lonza / Clonetics Corporation, Cat.CC3170), as well as 1% streptomycin-penicillin, 10% FBS (Sigma-Aldrich, Cat.F2442), 40 ug of luminescent ethanolamine (Sigma-Aldrich, Cat.P0503), and 3 ug of human recombinant EGF (Corning®, Cat.354052). THLE2 cells were cultured in flasks or plates pre-coated with 0.01 mg / ml fibronectin, 0.03 mg / ml type I bovine collagen, and 0.01 mg / ml bovine serum albumin. For HepG2 variants with stable knockout of Smad3 and / or Sptbn1 by CRISPR / Cas9, HepG2 cells seeded on a 6-well plate were transfected with Sptbn1 / HDR knockout CRISPR plasmids (Santa Cruz, sc-401818, sc-401818-HDR) using Lipofectamine LTX (Invitrogen) and Opti-MEM medium (Invitrogen) in 3 wells each, according to the manufacturer's instructions. After 48 hours, puromycin (5 μg / ml) was added to the medium for selection of stable knockout cells. The selection medium was changed every 2-3 days.

[0064] Method details reagent DMEM / F12 medium was obtained from Corning (Cat.10-090-CV), streptomycin-penicillin (Corning, Cat.30-002-Cl), fetal bovine serum was purchased from HyClone (Cat.SH30396.03), luminescent ethanolamine (Cat.P0503), and THEL2 was purchased from ATCC (ATCC Cat.CRL-2706).

[0065] Lipoprotein-deficient serum derived from fetal bovine cells was obtained from Sigma-Aldrich (Cat. S5394). The BEGM culture medium kit was obtained from Lonza / Clonetics Corporation (Cat. CC3170). Human recombinant EGF was purchased from Corning (Cat. 354052). Collagen-coated flasks for THLE2 cells were purchased from Thermo Scientific (Cat. 132707).

[0066] Targeting of SPTBN1 by siRNA in mouse and human 3D cultures For hydrodynamic injection of siRNA into the mouse tail, siSptbn1 and siCtrl were resuspended in nuclease-free water (Life Technologies) to 0.25 mM and incubated with RNAiMAX transfection reagent (Invitrogen) in a 1:1 ratio at room temperature for 20 minutes. These complexes were then diluted to 0.625 μM with TransIT®-QR hydrodynamic delivery solution (Mirus, Madison, WI). Mice were administered 2.0 mL of diluted siSptbn1 (1.25 nmol) or siCtrl by hydrodynamic tail vein injection as previously described. After feeding with HFD for 1 week, injections were repeated at 2-week intervals over 6 weeks. For a human three-dimensional perfusion microphysics system consisting of primary human hepatocytes, hepatic Kupffer cells, and stellate cells, these cells were co-cultured for 2 weeks in fatty acid, glucose, and insulin-fortified media as a culture model of human NASH.

[0067] Transfection and cell fractionation Cells seeded on 60 mm plates on day 0 were transfected on day 1 with 3–5 μg of the specified plasmid mix using Lipofectamine 3000 (Thermo Fisher Scientific, Cat. L3000015) according to the manufacturer's instructions. For TGF-β treatment on day 2, cells were incubated overnight in serum-free DMEM / F12 medium. Subsequently, TGF-β1 (Sigma-Aldrich, Cat. T1654; R&D, Cat. 240-B) was added at a final concentration of 200 pM over 0.5, 2, 12, 24, or 48 hours, after which cells were harvested. For knockdown experiments, siRNA targeting Sptbn1 or Smad3 (Dharmacon) was transfected into HepG2 or Hep3B cells with Lipofectamine RNAiMAX (Thermo Fisher, Cat. 13778150) over 24–48 hours.

[0068] For cell fractionation, cells were collected and lysed in cytoplasmic lysis buffer, followed by nuclear lysis buffer, according to the manufacturer's instructions for the nuclear / cytosol fractionation kit (Biovision, Cat.K266-25).

[0069] Immunoprecipitation and immunoblotting Treated or untreated cells were freshened using a cocktail of complete protease inhibitors and phosphatase inhibitors (Sigma-Aldrich, Cat. 4906845001, and Cat. 11836170001) (20 mM Tris-HCl). The samples were dissolved in pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton®-X100, 1% sodium deoxycholate, 0.1% SDS) or NP-40 lysis buffer (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1% NP-40, 1 mM EDTA), and then SDS-PAGE and immunoblotting were performed using the following antibodies: anti-SPTBN1 (in-hospital, rabbit), anti-SREBP1 (Abcam, Cat. Ab191857), anti-vinculin (Proteintech, Cat. 26520-1-AP), anti-GAPDH (Santa Cruz, Cat. sc-32233), anti-tubulin (Cell Signaling, Cat. 3873), and anti-Smad3 (Cell Signaling, Cat. 9513). For immunoprecipitation, each fractional lysate or whole cell lysate was pre-clarified for 30 minutes to remove nonspecific binding, and then immunoprecipitation was performed for 3 hours or overnight using protein A / G mix magnetic beads (MilliporeSigma®, Cat.LSKMAGAG02) mixed with anti-SPTBN1 (in-house) (23) or rabbit IgG as a control (Cell Signaling, Cat.2729). The immunoprecipitated complex (magnetic beads-lysate-antibody mix) was washed four times with washing buffer (10 mM EDTA-Tris, 150 mM NaCl, 20 mM MgCl2), eluted with sample buffer, and then performed Western blot analysis.

[0070] Luciferase assay For transcriptional reporter assays, 1 × 10⁶ HepG2 or Hep3B cells are used per well. 4Cells were seeded in 24-well dishes at the specified cell density. The following day, cells were co-transfected with siRNA (control or siRNA targeting Sptbn1 and Smad3) and a luciferase reporter (containing an LDLR promoter or an SCD promoter) using Lipofectamine 3000 (Thermo-Fisher, Cat.L3000015). - / - ) or Sptbn1 (Sptbn1 - / - MEF cells lacking ) Sptbn1 + / - For the wild type, Lipofectamine 3000 (Thermo Fisher, Cat.L3000015) was used to co-transfect cells with Renilla (Promega) using either the wild-type LDLR promoter region (pLDLR-luc, Addgene Cat.14940), the LDLR promoter region containing the SREBP nonresponsive mutant SRE (pLDLR-luc MUT, Addgene Cat.14945), or the SCD1 promoter (pGL3-SCD1, donated by Dr. Giovanni Sorrentino and Dr. Giannino Del Sal). For salvage experiments, pLDLR-luc or pGL3-SCD1 was used with Sptbn1 along with a control plasmid or V5-Sptbn1. - / - In MEF cells, or with the Flag-SMAD3 plasmid, Smad3 - / -MEF cells were co-transfected. Twenty-four hours after transfection, the cells were treated with 200 pM TGF-β1 (R&D, Cat. 240-B) for 24 hours and then serum-starved overnight. In all luciferase assays, the expression plasmid Renilla (Promega) served as an internal control to correct for transfection efficiency. Cells were extracted using 100 μl of luciferase cell culture lysis reagent. 10 microliters of cell extract was used for the measurement of Renilla enzyme activity. 20 microliters of cell extract was used for the luciferase assay using the Dual-Luciferase Assay Kit (Promega, Cat. E1980) according to the manufacturer's instructions. Luciferase activity was normalized to Renilla activity (AU) for each sample, and the fold change was calculated.

[0071] Immunohistochemical analysis and immunofluorescence analysis For immunohistochemical analysis, mouse tissues were fixed with 10% formalin and embedded in paraffin using standard procedures. FFPE sections were stained with hematoxylin and eosin (H&E) to evaluate the overall morphology and ballooning degeneration, stained with Oil Red to determine triglyceride accumulation, and stained with Sirius Red to determine fibrosis. Also, hepatocyte nuclear factor 4 (HNF4) (for hepatocytes), desmin (for hepatic stellate cells), CD31 (for hepatic sinusoidal endothelial cells), F4 / 80, CD142, ICAM1 (for macrophages), and CK19 (for cholangiocytes) were used to determine different cell types. Sections were labeled with antibodies specific for SPTBN1, SREBP1, and Smads (Cell Signaling Technology, 2899). Diaminobenzidine was used as a chromogen.

[0072] For immunofluorescence analysis, cells contained in DMEM / F12 supplemented with 10% FBS or 1% lipoprotein-deficient serum (LPDS) were plated at 2 × 10 4Cells were seeded at cell density on glass-bottomed dishes. Cells treated with oleic acid, staunosporin, and TNF-α at different time points, with or without TGF-β, were then fixed in 10% formalin for 15 minutes, followed by permeabilization with 0.1% saponin for 5 minutes. The cells were then incubated at room temperature for 1 hour with a blocking solution (PBS containing 0.1% saponin and 10% bovine serum albumin), followed by incubation overnight at 4°C with primary antibodies (1:200 anti-rabbit SREBP1, anti-rabbit Sptbn1, and anti-rabbit SMAD3). The following day, the cells were washed with PBS and incubated at room temperature for 1 hour with secondary antibodies (anti-rabbit Alexa Fluor Plus 488, goat anti-mouse Alexa Fluor 568, goat anti-rabbit Alexa Fluor 488, and Invitrogen). The nuclei were counterstained using DAPI. Images were acquired using an IX81 Olympus microscope and a confocal microscope with a 40x objective lens.

[0073] RNA extraction and RNA integrity Human RNA was isolated using the following protocol: Biopsy material was homogenized in STAT-60 (AMS biotechnology, CS-502) (1 ml), mixed (by vortex stirring), centrifuged at 13,000 g / RT for 5 minutes, the supernatant was mixed with 200 μl of chloroform (Sigma, Cat. 650471), centrifuged (12,000 g / 4°C / 15 mins), then mixed with 500 μl of isopropanol (Sigma, Cat. 33539), centrifuged (10,000 g / 4°C / 10 mins) to pelletize the RNA, washed the pellet with ethanol (75%; 1 ml), dried at room temperature, and the RNA was resuspended in DEPC-treated water (Quality Biological, Cat. 351-068-131). All reagents, plastic instruments, and equipment used were nuclease-free, sterile, and molecular biology grade. RNA purity (A260 / A280 > 1.80) and concentration were determined using Nanodrop (Thermo Fisher Scientific, Delaware, USA). RNA integrity was examined using a 2100 Bioanalyzer (RNA 6000 Nanokit, Agilent, Santa Clara, California, USA): an RNA integrity number (RIN) of 8 or higher was considered the minimum cutoff for sequencing. For mice, RNA was extracted from either liver tissue or hepatocytes using the RNeasy Plus Minikit (Qiagen, Cat. 74134). RNA quality and concentration were evaluated using a Thermo Scientific Nanodrop 3300 spectrophotometer, followed by RNA sequencing (Novogene Corporation). For real-time PCR analysis, total RNA was extracted using TRIzol reagent (Invitrogen, Cat.AM9738) according to the manufacturer's instructions. Reverse transcription of 1-2 ug of total RNA was performed using the Super-Script III first-strand kit (Invitrogen).Each cDNA was amplified in 3 replicates over 40 cycles using the iQ® SYBR Green SuperMix PCR kit (Bio-Rad Laboratories) in a Bio-Rad system (iCycler Thermal Cycler). The primers for real-time PCR are listed in the table below.

[0074] Whole transcriptome amplification and RNA sequencing One microgram of RNA was used to generate a barcoded sequencing library using the Illumina TruSeq® Stranded mRNA Library Preparation Kit (Illumina) according to the manufacturer's instructions. The sequencing libraries were normalized with respect to concentration and pooled into 96-plex pools. Sequencing was performed on three lanes of an Illumina HiSeq 4000 instrument at single-end 50bp (SE50) to obtain an average of 15 million reads / sample. Library preparation was performed by the Genomics and Transcriptomic Core at the Institute of Metabolic Sciences, and sequencing was performed at the Genomics Core, Cancer Research UK Cambridge Institute, both located at the University of Cambridge.

[0075] NGS data processing and statistical analysis RNA sequencing data from the human GRCh38 genome and mouse (GRCm38 / mm10) were aligned using hisat2 V2.1.0 2, and genes that passed QC were counted using HTSeq2 (v0.11.1) 3. Subsequently, proto-gene level counts were used for differential gene expression analysis using DESeq2 4. Gene expression was normalized using Log2-transformed copies per million (Log2CPM), and statistical significance (p<0.05) was evaluated using R with the Wald test in DESeq2. Subsequently, the original p-values ​​were adjusted using the Benjamini-Hochberg procedure to suppress the false discovery rate (FDR) 5.

[0076] Bioinformatics Functional Analysis Using Ingenuity Pathway Analysis (IPA, Qiagen), the entire transcriptome was assigned, and statistically significant (p<0.05) hits were filtered in IPA to identify genes differentially expressed within groups, where Log2FC was below -0.3785 or above 0.3785, Log2CPM > 0.5 in humans, and / or FPKM > 1 in mice. Upstream regulatory network was generated and ranked by the importance (p<0.05 in humans) and activation status (Z-score) of the involved genes. The inventors considered only genes that were statistically significant (p<0.05), had a Log2FC below -0.3785 or above 0.3785, showed enhanced "significantly regulated" networks in comparative analysis, and / or had an FDR < 0.05 to be "biologically important".

[0077] Structural modeling of human SPTBN1 and SREBP1c The three-dimensional structures of human SPTBN1 and SREBP1c remain unknown. Therefore, in-silico structural modeling was performed using a homology-based folding structure recognition method with the Phyre2 (Protein Homology / analogY Recognition Engine V 2.0) server (53) on the web. This method generates a three-dimensional model of the protein structure using multiple templates that cover different query regions of the amino acid sequence (which have different identification information and therefore varying levels of confidence). First, templates were identified using P-BLAST (Protein Basic Local Alignment Search Tool) against the RCSB Protein Databank (PDB). Several templates were found that showed suitable sequence identity and overlap rates with SPTBN1 and SREBP1c, and could serve as models for their structures. Using the template from the PDB with the highest sequence identity and overlap rate, and the folding structure from the in-house Phyre folding library, models of human SPTBN1 and SREBP1c were generated (Table 2). We optimized the loop model using ModLoop(54) and then performing model optimization using Swiss-PDB Viewer(55). [Table 2]

[0078] Furthermore, model optimization and energy minimization were performed to avoid any resulting errors and high-energy configurations that could lead to physical disruption and instability of the structure, thereby finding the most stable and lowest-energy conformations for SPTBN1 and SREBP1c. Swiss-PDB Viewer was used for energy minimization and structural optimization by changing the coordinate geometry in a way that releases internal strain and reduces the total potential energy of the model.

[0079] Structure-based molecular docking Furthermore, after modeling the structures of SPTBN1 and SREBP1c, their binding modes were investigated by using molecular docking techniques. The structural coordinates of the SPTBN1 fragment encompassing D50~T975, Q1132~T2155, and A2198~K2364, and the SREBP1c fragment encompassing Q295~K374 and P546~S705 were obtained from the inventors' model structures. Docking was performed using the ClusPro 2.0 web server (38). First, the docking results were screened to obtain higher binding affinity, and then the highest-level docking conformation was selected, and their possible interactions were further analyzed using PyMOL and LigPlot+.

[0080] statistics Differences between the two groups were assessed using Student's two-tailed t-tests with GraphPad Prism. Pairwise comparisons were performed for weekly weight gain. One-way ANOVA with post-hoc Bonferroni tests was used for multiple comparisons. In vitro experiments were performed 2–4 times. All luciferase experiments were performed at least 3 times with 3 replicates. Unless otherwise indicated, results are expressed as mean ± standard deviation. In all statistical analyses, p < 0.05 was considered statistically significant.

[0081] Various human and mouse sequence lists Homo sapiens spectrin beta, non-erythrocyte type 1 (SPTBN1), transcription variant 1, mRNA NCBI reference sequence: NM_003128.3

[0082] Homo sapiens spectrin beta, non-erythrocyte type 1 (SPTBN1), transcription variant 2, mRNA NCBI reference sequence: NM_178313.2

[0083] Mouse spectrin beta, non-erythrocyte type 1 (Sptbn1), transcription variant 1, mRNA NCBI reference sequence: NM_175836.2

[0084] Mouse spectrin beta, non-erythrocyte type (Sptbn1), transcription variant 2, mRNA NCBI reference sequence: NM_009260.2

[0085] Mouse siRNA targeting Sptbn1 Target sequence:

[0086] Sense: CGAUGUUACAAGAACGGUUTT (Sequence ID 5).

[0087] Antisense: AACCGUUCUUGUAACAUCGTG (Sequence ID 6).

[0088] Targeted approach using human siRNA Target sequence: CCUGAAAGUGAGCGCAUUA (Sequence ID 7).

[0089] Target sequence: CCGCAUACGAGGAGCGUGU (Sequence ID 8).

[0090] Target sequence: GGACAUGUCUUACGAUGAA (Sequence ID 9).

[0091] Target sequence: GUGACAGGCCGACGAUAU (SEQ ID NO: 10).

[0092] Example 1 Liver-specific low SPTBN1 knockout protects mice from HFD-induced NASH. We created liver-specific conditional SPTBN1 (Sptbn1-flox) knockout mice (LSKO) lacking hepatocyte SPTBN1 (Supplementary Figures 1A, B). LSKO mice were viable and fertile. Hepatocyte-specific deletion of SPTBN1 was confirmed by the absence of detectable protein by immunoblotting or immunohistochemical staining (Supplementary Figures 1B, C). Hepatic histology and metabolic characteristics were evaluated for LSKO mice fed a normal diet (Supplementary Figures 1D-H). On a normal diet, LSKO mice had a similar body weight to Flox control mice (Supplementary Figure 1E), but LSKO mice exhibited significantly lower serum triacylglycerol (TG) (Supplementary Figure 1F) and blood glucose (Supplementary Figure 1G) concentrations, and slightly increased insulin sensitivity in insulin resistance tests (Supplementary Figure 1H). Histologically, compared to Flox mice, the livers of LSKO mice showed reduced lipid accumulation (Supplementary Figure 1D). In addition, LSKO mice and Flox control mice had similar levels of food and water intake, as well as urinary excretion (Supplementary Figure 2A).

[0093] The effects of HFD were evaluated using LSKO mice. Male and female Flox control and LSKO mice aged 10–12 weeks were placed in HFD for 12–20 weeks (Figure 1A). In HFD, 60% of calories were from fat (29–31). After 12 weeks in HFD, diet and water intake, as well as urinary excretion, were similar between Flox control and LSKO mice (Supplementary Figure 2A). However, after 12 weeks of HFD, LSKO mice gained less weight, had less visceral fat, and were protected from HFD-induced obesity (Figure 1B). Metabolic profile evaluation showed that HFD-fed LSKO mice had lower serum triglyceride (TG) concentrations, but serum glucose and total cholesterol concentrations were similar to those of HFD-fed Flox control mice (Figure 1C). The livers of HFD-fed LSKO mice were smaller than those of HFD-fed Flox control mice, even though both mouse genotypes had similar levels of Ki67-labeled proliferating cells in their livers (Supplementary Figure 2B) (Figure 1D). Analysis of liver function by measuring serum aspartate transaminase (AST) and alanine transaminase (ALT) concentrations showed lower concentrations in LSKO mice, suggesting better liver function and less liver damage in HFD-fed LSKO mice compared to HFD-fed Flox control mice (Figure 1D).

[0094] Consistent with less liver damage in HFD-fed LSKO mice, liver histology of these mice revealed normal liver structure, minimal lipid accumulation, and the absence of signs of ballooning degeneration or inflammation that can occur in the liver (Figure 1E). Electron microscopy revealed fibrosis, indicated by collagen deposition in the extracellular matrix, and steatosis, indicated by lipid droplet accumulation, in the livers of HFD-fed Flox mice, but these changes were absent in the livers of HFD-fed LSKO mice (Figure 1F). Compared to livers from HFD-fed Flox mice for 16 weeks, livers from LSKO mice showed reduced expression of TGF-β / SMAD3-regulated genes associated with hepatic fibrosis, altered expression of inflammation-related genes, and reduced expression of genes encoding proteins involved in fatty acid metabolism (Figure 1G).

[0095] Changes in Flox control mice indicated that 16 weeks of HFD led to progression to NAFLD, accompanied by progression to NASH. Furthermore, LSKO mice were protected from this diet-induced hepatopathy. LSKO mice fed HFD were found to be protected from obesity and progression to NAFLD, as well as progression to NAFLD and progression to HCC.

[0096] Example 2 SPTBN1 regulates the SREBP pathway and fatty acid metabolism. To understand how liver-specific loss of SPTBN1 protects mice from liver disease, we conducted targeted studies on specific key regulators in Flox and LSKO mice fed HFD for 16 weeks and investigated differences in gene expression in the livers of Flox and LSKO mice after 16 weeks of HFD by performing a comprehensive liver metabolite analysis of RNA sequencing (RNA-seq) data. We examined the transcript and protein abundances of the transcription factor C / EBPα, which regulates adipogenesis (32) and uncoupling protein 2 (UCP2), reduces mitochondrial ATP production, and is associated with NASH (33). For any of these, there were no differences in the levels of transcript or protein abundance in the livers of HFD-fed Flox and LSKO mice (Supplementary Figure 2C). Bioinformatics analysis using Ingenuity Pathway Analysis (IPA) showed that some pathways associated with differentially expressed genes were linked to stress or infection (Figure 2A). Ingenuity analysis of differentially regulated genes in LSKO mice showed associations with decreased or reduced activity of the transcription factors SREBP, PPARγ (peroxisome proliferator-activated receptor γ), and PPARα, which regulate lipid and cholesterol metabolism, as well as the transcription factor XBP1, which is activated by ER stress (Figure 2A). Based on the association between SPTBN1 loss in the liver and a decrease in the SREBP and PPARG lipid pathways, we examined limited mass spectrometry data to identify proteins co-immunoprecipitated with V5-tagged SPTBN1 from stressed HEK293T cells and associated them with nascent lipid biosynthesis or its regulation (Table 3). Unexpectedly, based on these data, SREBP1 appeared to be a potential binding partner of SPTBN1. Therefore, we focused on SREBP1. [Table 3]

[0097] Since SPTBN1 has a scaffolding function in both the cytoplasm and the nucleus, we evaluated whether the distribution or abundance of SREBP1 in the liver changed in LSKO mice fed either a normal diet or HFD. In the livers of Flox mice fed a normal diet, SREBP1 had a concentrated punctate distribution, and there were almost no cells showing nuclear staining (Figure 2B, bottom). In mice fed HFD for 12-16 weeks, most hepatocytes in the livers of Flox control mice had nuclear localized SREBP1, which was consistent with SREBP1 activation. In the livers of LSKO mice fed either a normal diet or HFD, SREBP1 staining was not very concentrated, and in the livers of HFD-fed LSKO mice, there were fewer cells with nuclear SREBP1, suggesting lower SREBP1 activity (Figure 2B). In mice fed a normal diet, no difference in SREBP1 transcript levels was detected in the livers of Flox control and LSKO mice (Supplementary Figure 2D), indicating that the decrease in SREBP1 levels is not mediated at the gene expression level.

[0098] There are two genes encoding SREBP1 and SREBP2. Therefore, the abundance of precursor SREBP (ER-localized full-length SREBP) and n-SREBP (cleaved nuclear SREBP) was evaluated for both proteins, as well as for their ER localization regulators SCAP and INSIG in the livers of Flox and LSKO mice fed a normal diet or HFD for 12–16 weeks. In the normal diet or HFD groups, the abundance of SCAP and INSIG was similar between Flox and LSKO mice, while SCAP showed a consistent decrease in abundance in mice fed HFD (Figure 2C). In addition, siRNA-mediated knockdown of SPTBN1 in THLE2 human hepatocytes did not affect INSIG1 abundance (Supplementary Figure 2E). Although there was variation among individual mice, precursor SREBP1 and n-SREBP1 appeared to be reduced in the livers of LSKO mice fed a normal diet or HFD compared to the livers of Flox control mice fed a normal diet (Figure 2C). In HFD-fed mice, the amount of precursor SREBP2 was similar to or slightly less than that of Flox control mice, but the amount of n-SREBP2 appeared to be similar to or slightly less than that of LSKO mouse livers (Figure 2C). Therefore, the decrease in SREBP1 abundance detected by immunohistochemistry and immunoblotting in LSKO mouse livers was not due to changes in the abundance of SREBP ER localization regulators or impaired SREBP1 gene expression.

[0099] To determine whether the decrease in SREBP1 in LSKO mouse liver corresponds to a decrease in SREBP1 target gene expression, we analyzed either the transcript and protein abundance of nascent lipid biosynthesis gene products or a luciferase reporter assay performed using an SRE-containing promoter. In the livers of mice fed a normal diet or HFD for 12–16 weeks, ACC1 (encoding acetyl-CoA carboxylase 1), SCD1 (encoding stearoyl-CoA desaturase-1), and FASN (encoding fatty acid synthase) were lower in LSKO tissue, and these changes were reflected in the lower protein levels (Figure 2D, E). Therefore, we detected the decrease in SREBP1 target gene expression in the absence of SREBP1. Consistent with the minimal differences observed in SREBP2 abundance in the livers of Flox and LSKO mice, the transcript of LDLR(34), the main target of SREBP2 in cholesterol metabolism, was found to be similar in the mouse livers, as was the amount of LDLR protein (Figure 2D, E). The data suggested that SPTBN1 predominantly regulates SREBP1 rather than SREBP2.

[0100] The SREBP-responsive luciferase assay uses a luciferase reporter containing wild-type SRE from the LDLR promoter region (LDLR-luc), a SREBP-unresponsive mutant SRE (mut-LDLR-luc), or an SRE from the SCD1 promoter (SCD-luc), and is based on mouse embryonic fibroblast (MEF) cells isolated from wild-type mice and systemic Sptbn1 - / - The study was conducted in which serum starvation (35), which activates SREBP in cultured cells, was found to increase SRE-dependent LDL-luc and SCD-luc activity in wild-type MEFs, and Sptbn1 - / - In cells, SRE-dependent luciferase activity was found to be absent or minimal (Figure 2F), indicating that SREBP1-dependent target gene expression is impaired in the absence of SPTBN1. - / -Re-expression of SPTBN1 in MEF cells restored SRE-dependent luciferase activity (Figure 2G). An evaluation to determine whether TGF-β stimulates SRE-dependent gene expression revealed that TGF-β stimulated SRE-dependent luciferase activity in an SPTBN1-dependent manner (Figure 2F), suggesting that TGF-β signaling involving SPTBN1 may also contribute to nascent lipid biosynthesis.

[0101] WT or SMAD3 - / - We conducted experiments using a luciferase reporter gene expressed in MEF to investigate whether SMAD3-mediated TGF-β signaling affects SRE-dependent gene expression. The tendency for SRE-induced gene expression to increase was observed with SMAD3. - / - This was observed in MEF (Figure 2H, left). As a positive control, luciferase expression stimulated by TGF-β was observed in SMAD3 - / - The data originated from the SMAD-dependent promoter of WT MEF, not from MEF (Figure 2H, right). These data indicated that SMAD3-mediated TGF-β signaling does not contribute to TGF-β-mediated enhancement of SRE-dependent gene expression.

[0102] Example 3 SPTBN1 binds to SREBP1. To verify the mass spectrometry data (Table 3) suggesting that SPTBN1 and SREBP1 are parts of the same complex, SPTBN1 was immunoprecipitated from three HCC cell lines. Progenitor SREBP1 and n-SREBP1 were detected in the immunoprecipitates from all three cell lines (Figure 3A, Supplementary Figure 3A), indicating that the interaction between SPTBN1 and precursor SREBP1 occurred in the cytoplasm (Supplementary Figure 3B).

[0103] To explore the structural basis of the binding between SPTBN1 and SREBP1 and to map potential interaction sites, the three-dimensional structures of SPTBN1 and SREBP1c were modeled, and then molecular docking simulations based on the structure were performed. Two splice manifolds of SREBP1 exist: SREBP1a and SREBP1c (36). SREBP1c was selected for the molecular docking simulation because it is the form that specifically stimulates fatty acid synthesis and is associated with hepatic steatosis (37).

[0104] SPTBN1 consists of 2,364 amino acid residues and is characterized by multiple homologous tandem spectrin repeats, each consisting of three antiparallel helices adjacent to a pair of carponin-homologous (CH) domains at the N-terminus and a plextrin-homologous (PH) domain at the C-terminus (Figure 3B). SPTBN1 has a caspase-3 cleavage site (1454DEVD1457) in the 11th spectrin repeat. SREBP1c consists of 1,047 amino acid residues forming an N-terminal DNA-binding domain (bHLH), two transmembrane domains, each with a central cleavage site, and a C-terminal regulatory domain. SREBP1c has a caspase-3 cleavage site (433SEPDSP438) in front of the transmembrane domain (12) (Figure 3B).

[0105] For modeling purposes, SPTBN1 was tested in three fragments encompassing D50-T975, Q1132-T2155 (Figure 3C), and A2198-K2364 (Supplementary Figure 3C), and SREBP1c was modeled in two fragments encompassing Q295-K374 (Figure 3C) and P546-S705. SREBP1c P546-S705 cannot be docked onto SPTBN1. However, the interaction was successfully simulated between the SREBP1c Q295-K374 fragment and SPTBN1 (Figures 3C, D; Supplementary Figure 3C; Table 4).

[0106] The model predicted that SREBP1c Q295~K374 would conform to SPTBN1 binding cavities with high affinity, and that the interaction would be stabilized by multiple hydrogen bonds and van der Waals interactions (Table 4). Based on the lowest interaction energy values ​​(38,39), the predicted models were ranked according to their affinity as follows (Table 4): SREBP1c Q295~K374 / SPTBN1 Q1132~T2155 (Figure 3D) > SREBP1c Q295~K374 / SPTBN1 D50~T975 (Figure 3C) >> SREBP1c Q295~K374 / SPTBN1 A2198~K2364 (Supplementary Figure 3C). In summary, docking analysis predicted that SPTBN1 fragments D50-T975 and Q1132-T2155 were preferred SREBP1c Q295-K374 binding sites. [Table 4]

[0107] To test the predictive model, SREBP1 and SPTBN1 fragments were generated to identify the region required for their interaction. Starting with N-SREBP1 (amino acids M1-L466), four fragments (Figure 3D) were generated. Fragment 2 of SREBP1 corresponds to the modeled region (Q295-K374) and co-immunoprecipitated more effectively with full-length V5-tagged SPTBN1 (Figure 3D). Indeed, this region was required for the interaction. Caspase 3 cleaves SPTBN1 into two products, N-SPTBN1 (amino acids M1-D1454) and C-SPTBN1 (E1455-K2364), which are detected in acetaminophen-damaged liver (27). N-SPTBN1 and C-SPTBN1 were generated to be tagged with V5, but only N-SPTBN1 was found to co-immunoprecipitate with Flag-tagged n-SREBP1 (Figure 3E). These data suggest that SPTBN1 and SREBP1 can directly interact. From modeling and fragment interaction analysis, it was hypothesized that conditions that induce caspase-3 activation in cells lead to cleavage of SPTBN1, which facilitates the interaction between N-SPTBN1 and n-SREBP1.

[0108] Example 4 In human hepatocytes and HCC cells, cellular stress induces caspase-3-dependent cleavage of both SREBP1 and SPTBN1. Stress-induced caspase activation is associated with the NASH phenotype (8, 9). RNA-seq data revealed changes in the ER stress and UPR pathway in the liver of HFD-fed LSKO mice (Figure 2A). Since both SREBP1 and SPTBN1 are substrates of caspase-3 (12, 27), and interaction data suggested that their cleavage products interact (Figure 3E, F), the relationship between caspase-3, SPTBN1, and SREBP1 was investigated in immobilized human hepatocyte cell line THLE2 and HCC cell line Huh7. Caspase-3 activation was induced using TNFα and cycloheximide or palmitic acid (PA). TNFα and PA induced caspase-3 activation in hepatocytes (40, 41) and were associated with the progression to NASH (42, 43). THLE2 cells exposed to TNFα and cycloheximide exhibited caspase 3 activation (cleavage caspase 3), SREBP1 activation (n-SREBP1), and SPTBN1 cleavage producing both N-SPTBN1 and C-SPTBN1 (Figure 4A). Analysis of the cytosolic and nuclear distribution of N-SPTBN1 and C-SPTBN1 expressed as V5-tagged proteins in THLE2 cells showed that N-SPTBN1 was present in both the cytoplasm and nucleus, while C-SPTBN1 was detected only in the cytoplasm (Figure 4B). Knockdown of SPTBN1 in Huh7 cells did not attenuate caspase 3 activation induced by TNFα and cycloheximide or SREBP1 cleavage under these conditions (Figure 4C). However, expression of SCD1, a SREBP1 target gene, was reduced (Figure 4C). In this HCC cell line exposed to TNFα and cycloheximide, impaired expression of the SREBP2 target gene LDLR was observed (Figure 4D), which is in contrast to findings in the liver of LSKO mice fed a normal diet (Figure 2E), and may be related to the lack of stress under in vivo conditions.

[0109] Exposure of Huh7 cells to PA induced caspase-3 activation, which was reduced by the caspase-3 inhibitor (Z-DEVD-FMK) (Figure 4E). PA also induced SPTBN1 cleavage, which was also reduced by the caspase-3 inhibitor, indicating that SPTBN1 cleavage is dependent on caspase-3 activity (Figure 4E). Progenitor SREBP1 and SPTBN1, as well as N-SPTBN1, were found to be immunoprecipitated from PA-exposed Huh7 cells, which is consistent with the interaction between SREBP1 and SPTBN1 mediated by the caspase-3 cleavage product N-SPTBN1 (Figure 4F). In PA-treated cells with SPTBN1 knocked down, caspase-3 activation was unaffected, but N-SREBP was reduced, suggesting that the interaction with SPTBN1 may stabilize n-SREBP1 (Figure 4G).

[0110] In hepatocytes under stress or cultured with large amounts of PA, caspase-3 cleaved both SREBP1 and SPTBN1, and the cleavage products interacted to stabilize the nuclear morphology of SREBP1, thereby promoting nascent lipid biosynthesis.

[0111] Biochemical data demonstrated a mechanistic relationship between non-apoptotic caspase 3 activity and nascent lipid biosynthesis through nSREBP formation and stabilization of nSREBP1 via interaction with caspase-cleaved N-SPTBN1. This provides a second pathway, other than ER stress-induced activation of SREBP, for abnormal activation of nascent lipid biosynthesis leading to lipidization and progression to NAFLD. The data suggested that caspase-mediated activation of SREBP1 is independent of changes in SCAP and INSIG, which are ER localization regulators of SREBP activation (6, 52), thereby bypassing normal regulation that limits nascent lipid biosynthesis under sufficient or excess lipid conditions.

[0112] Example 5 Human NASH is associated with increased SPTBN1 and CASPASE3 expression, as well as enhanced TGF-β pathway and SREBP1 activity. To gain insight into the validity of findings linking the caspase-3 mediated interaction pathway between SPTBN1 and its cleavage products with SREBP1 to steatosis, we analyzed data from four publicly available databases containing information on healthy obese individuals and patients with NAFLD, NASH, or HCC. Using Ingenuity “upstream regulator” analysis, we evaluated proteins associated with differences in gene expression between early NASH (NASH1 and 2) and NAFLD, and between late NASH (NASH3 and 4) and NAFLD. Consistent with the involvement of TGF-β signaling in fibrosis, the upstream regulators with increased activity, which were key indicators of NASH progression from NAFLD (14, 44, 45), included several proteins within the TGF-β pathway, with the only downregulated protein being SMAD7, an inhibitor of TGF-β signaling (Figure 5A).

[0113] Liver tissue data from healthy obese individuals were compared with those from NASH patients for the transcripts of SPTBN1, caspase 3, SREBP1, and SMAD3, as well as for SREBP1 target genes involved in lipid biosynthesis. Both SPTBN1 and caspase 3 transcripts were increased in NASH patients, while no difference was observed for SREBP1 and SMAD3 (Figure 5B). Significant increases in the expression of FASN, SCD, and AACS were found, suggesting increased SREBP1 activity (Figure 5C).

[0114] Since NASH implies a high risk of progression to HCC (1), single-cell RNA-seq was performed to examine SPTBN1 expression in liver tissue from patients with both NASH and HCC but without cirrhosis. A subset of cells with high SPTBN1 expression was identified (Figure 5D, Table 1): five subtypes of hepatocytes (Hep-1, Hep-4, Hep-5, Hep-6, and Hep-7), both types of cholangiocarcinomas (Chol-1 and Chol-2), and portal vein hepatic sinusoidal endothelial cells (LSEC-PP). Analysis of the single-cell RNA-seq data showed that hepatocytes with high SPTBN1 expression were clustered together when plotted on a phenograph (Figure 5E). The amount of SPTBN1 was confirmed to be higher in liver tissue from NASH patients compared to liver tissue from healthy controls (Figure 5F).

[0115] In summary, the evaluation of human NASH liver data is consistent with findings from HFD-fed mice suggesting that SPTBN1 is involved in the progression of this disease. Furthermore, these data support the idea that in addition to increased SPTBN1 and caspase 3 levels, TGF-β / SMAD signaling and SREBP1-dependent gene expression activity are increased in NASH.

[0116] Example 6 In vivo siRNA-induced targeting of SPTBN1 weakens HFD-induced NAFLD and NASH. Liver disease is one of the few diseases for which there is an FDA-approved siRNA-based therapy (46). Therefore, we conducted an experiment to investigate whether siRNA-mediated knockdown of SPTBN1 in Flox mice protects it from HFD-induced NAFLD and NASH. Flox mice (10-12 weeks old) were fed HFD for 12 weeks. One week after the start of HFD, mice were hydrodynamically injected with either SPTBN1-targeting siRNA (siSptbn1) or an equivalent volume of siRNA-negative control (siCtrl) every two weeks for a total of three injections (Figure 6A). Mice were followed up weekly for weight gain and survival. SPTBN1 knockdown was confirmed by siSptbn1 in the liver of Flox mice at the end of the experiment (Figure 6A, right). In all parameters, siSptbn1-treated mice responded to HFD similarly to LSKO mice. Compared to siCtrl-treated mice, siSptbn1-treated mice showed significantly less weight gain (Figure 6B), less visceral fat accumulation (Figure 6C), lower blood TG levels, and similar blood glucose levels (Figure 6D). The histology, lipid accumulation, and expression of pro-fibrosis and inflammatory genes in the liver of siSptbn1-treated mice were similar to those of LSKO mice, with significantly less expression of pro-fibrosis and inflammatory genes compared to the livers of siCtrl-treated mice (Figure 6E), and possessed normal liver structure and low lipid accumulation without any signs of NAFLD or NASH (Figure 6F).

[0117] The same benefits of siSPTBN1 were observed in liver-specific SPTBN1 heterozygous mice (LHET) (Supplementary Figures 4A, B) and female Flox mice (Supplementary Figure 4C). Therefore, siSPTBN1 treatment, when initiated early in the period of HFD intake, prevented progression to NAFLD and NASH in mice.

[0118] The hepatocyte-specific absence of SPTBN1 clearly had no adverse effects on liver morphology or function, and SPTBN1-targeting siRNA was an effective therapeutic agent in mitigating the progression to HCC in preclinical mouse NASH models and chemically induced mouse models. In addition, acetaminophen is a commonly used commercial drug with hepatotoxicity (51). Low doses of acetaminophen induce phosphorylation of TGFBR2 and SMAD signaling, and higher toxic doses promote caspase activation, leading to the generation of caspase-cleaved SPTBN1 and severe hepatotoxicity (27). The data suggest that targeting SPTBN1 may be a useful therapy for preventing acetaminophen hepatotoxicity.

[0119] The results positioned SPTBN1 as a key player in both steatosis and fibrosis in response to HFD: as a substance participating in TGF-β / SMAD3 signaling, SPTBN1 promotes fibrosis, and as a substance participating in stress-activated SREBP1 signaling, SPTBN1 promotes nascent lipid biosynthesis and steatosis.

[0120] Example 7 SPTBN1 knockdown in a human three-dimensional cultured NASH model mitigates transcriptional changes associated with NASH. Mouse results showed that SPTBN1 knockdown prevented progression to HFD-induced NAFLD and NASH. This potential therapy was also tested in a newly developed three-dimensional perfusion microphysics system that allowed for the co-culture of primary human hepatocytes, hepatic Kupffer cells, and stellate cells for two weeks in fatty acid, glucose, and insulin-enriched media as a culture model of human NASH (47, 48). Three-dimensional cultures were exposed to different concentrations of siSptbn1 and equivalent concentrations of siCtrl by applying siRNA on days 4 and 6 (Figure 6G). Treatment with 25 nM siRNA resulted in a reduction of over 90% in SPTBN1 transcripts after 96 hours (Figure 6H, left). No significant differences were observed in lipid accumulation on days 8 or 14 (2 or 7 days after siRNA addition), but there was a tendency for decreased levels in siSptbn1-treated cultures (Figure 6H, right).

[0121] RNA-seq analysis was performed on cultures exposed to siSptbn1 (25 nM or 50 nM) or siCtrl for several days, using samples collected 96 hours after siRNA treatment. Pathway analysis revealed a significant decrease in transcripts encoding proteins involved in lipid transport, triglyceride and glycogen metabolism, and fatty acid metabolism, including those involved in lipoprotein catabolism, in siSptbn1-treated cultures (Figure 6I). Decreases were also observed in transcripts encoding proteins involved in fibrosis and altered inflammatory gene expression in siSptbn1-treated cultures (Figure 6I). These changes indicated that siSptbn1 treatment reduced nascent lipid biosynthesis, inflammation, and fibrosis. As expected, siSptbn1-treated cultures showed a significant decrease in gene expression signatures related to TGF-β signaling (Supplementary Figure 4E), which is consistent with mouse models that show this profile is reduced in LSKO and activated in mouse (HFD-induced NASH) and human NASH (Supplementary Figure 4E).

[0122] Analysis of "upstream regulators" by IPA showed that regulators exhibiting higher activity in human NASH compared to NAFLD were uniformly associated with lower activity in siSptbn1-treated cultures compared to siCtrl-treated cultures (Figure 5J). Furthermore, upstream regulators exhibiting lower activity in NASH than NAFLD were found to exhibit higher activity in siSPTBN1-treated cultures compared to siCtrl-treated cultures (Figure 5J). Therefore, siSptbn1 appears to reverse or counteract regulatory changes associated with NASH, further supporting the concept of siSptbn1 as a protein therapy.

[0123] Example 8 LSKO mice are mice protected from HFD-induced HCC. Data showed that complete liver-specific loss of SPTBN1 protected mice from HFD-induced NASH, a well-established risk factor for HCC (1). Here, we evaluated the involvement of homozygous loss of hepatic SPTBN1 in relation to HCC. First, we examined the incidence of HCC in LSKO and LHET mice fed HFD for 20 weeks. Two tumor nodules were found in four HFD-fed LHET mice, but no liver tumors were found in any of the age-matched HFD-fed LSKO mice (Figure S7A). Progression to HCC did not occur frequently enough under these experimental conditions, so we switched to a chemically induced HCC model.

[0124] Diethylnitrosamine (DEN) was used to induce HCC. Progression to liver tumors was evaluated at 24 or 40 weeks after DEN injection. All Flox control mice, LHET mice, and LSKO mice developed tumors in this model, while LSKO mice were relatively protected (Figure 7B, C; Figure S7B). Small nodules were found in the liver at 24 weeks after DEN injection (Figure 7B), and progressed to tumors by 40 weeks (Figure 7B, C; Figure S7B). Most LSKO mice had a lower tumor burden, indicated by a lower tumor number, smaller tumor size, and improved liver pathology compared to Flox control mice (Figure 7B, C). Furthermore, the livers of LSKO mice showed fewer proliferating cells, indicated by Ki67 labeling, compared to the livers of Flox control mice (Figure 7D). However, no significant difference was observed in labeling with caspase-3, a marker of apoptosis, suggesting that the reduced tumor burden in LSKO mice was not due to increased apoptosis (Figure 7E). Consistent with the LSKO HCC protective phenotype, STAT4 (49, 50), an HCC inhibitor, was identified as an activating upstream regulator of differentially regulated genes in the liver of LSKO mice fed HFD (Figure 2A).

[0125] To investigate whether complete loss of SPTBN1 has a protective effect in human HCC, the frequency of homozygous loss (deep deletion) of SPTBN1 was analyzed in human HCC. In the data from TCGA, only one patient (0.2%) had homozygous loss of SPTBN1 (1 / 440), while heterozygous deletion occurred in 7.8% (30 / 440) of HCC patients (30 / 440). Evaluation of SPTBN1 copy number changes in 33 cancer types in the TCGA data also showed that homozygous loss of SPTBN1 is rare, with an overall frequency of 0.1% across 33 cancer types representing 33,039 cancer patients (Figure 7F). Therefore, the human cancer outcomes suggest that the findings from LSKO mice are translationally important and that loss of SPTBN1 protects against the progression of NASH and development into HCC.

[0126] All features described herein (including any attached claims, abstracts, and drawings) and / or all steps of any method disclosed herein may be combined with any of the embodiments described herein in any combination except in which at least some of such features and / or steps are mutually exclusive.

[0127] It should be understood that the above embodiments and examples are not intended to limit the scope of this disclosure in any way, and that the claims provided herein are intended to encompass all embodiments, examples, and examples, whether expressly provided herein or otherwise.

[0128] By reference, all patents, patent applications, and publications listed herein are fully incorporated.

[0129] References 1.Q.M.Anstee,H.L.Reeves,E.Kotsiliti,O.Govaere,M.Heikenwalder,From NASH to HCC:current concepts and future challenges.Nat Rev Gastroenterol Hepatol 16,411-428(2019)。

[0130] 2.Z.Liu et al.,Global incidence trends in primary liver cancer by age at diagnosis,sex,region,and etiology,1990-2017.Cancer 126,2267-2278(2020)。

[0131] 3.N.Chalasani et al.,The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases.Hepatology 67,328-357(2018)。

[0132] 4.M.Yarchoan et al.,Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.Cancer Res 79,4326-4330(2019)。

[0133] 5.S.L.Friedman,B.A.Neuschwander-Tetri,M.Rinella,A.J.Sanyal,Mechanisms of NAFLD development and therapeutic strategies.Nat Med 24,908-922(2018)。

[0134] 6.B.A.Neuschwander-Tetri,Non-alcoholic fatty liver disease.BMC Med 15,45(2017)。

[0135] 7.D.Kumar,G.C.Farrell,C.Fung,J.George,Hepatitis C virus genotype 3 is cytopathic to hepatocytes:Reversal of hepatic steatosis after sustained therapeutic response.Hepatology 36,1266-1272(2002)。

[0136] 8.J.Y.Kim et al.,ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P.Cell 175,133-145 e115(2018)。

[0137] 9.P.Zhao et al.,An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.Science 367,652-660(2020)。

[0138] 10.H.Shimano,R.Sato,SREBP-regulated lipid metabolism:convergent physiology-divergent pathophysiology.Nat Rev Endocrinol 13,710-730(2017)。

[0139] 11.R.A.DeBose-Boyd et al.,Transport-dependent proteolysis of SREBP:relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi.Cell 99,703-712(1999)。

[0140] 12.X.Wang et al.,Cleavage of sterol regulatory element binding proteins(SREBPs)by CPP32 during apoptosis.EMBO J 15,1012-1020(1996)。

[0141] 13.M.Ekstedt et al.,Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology 61,1547-1554(2015)。

[0142] 14.A.Wree,L.Broderick,A.Canbay,H.M.Hoffman,A.E.Feldstein,From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.Nat Rev Gastroenterol Hepatol 10,627-636(2013)。

[0143] 15.N.Sanderson et al.,Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.Proc Natl Acad Sci U S A 92,2572-2576(1995)。

[0144] 16.K.C.Flanders,Smad3 as a mediator of the fibrotic response.Int J Exp Pathol 85,47-64(2004)。

[0145] 17.H.Yadav et al.,Protection from obesity and diabetes by blockade of TGF-beta / Smad3 signaling.Cell Metab 14,67-79(2011)。

[0146] 18.A.Majumdar et al.,Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol 9,530-538(2012)。

[0147] 19.V.Bennett,Spectrin-based membrane skeleton:a multipotential adaptor between plasma membrane and cytoplasm.Physiol Rev 70,1029-1065(1990)。

[0148] 20.V.Bennett,D.N.Lorenzo,An Adaptable Spectrin / Ankyrin-Based Mechanism for Long-Range Organization of Plasma Membranes in Vertebrate Tissues.Curr Top Membr 77,143-184(2016)。

[0149] 21.A.Viel,D.Branton,Spectrin:on the path from structure to function.Curr Opin Cell Biol 8,49-55(1996)。

[0150] 22.Y.Tang et al.,Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice.Science 299,574-577(2003)。

[0151] 23.J.Chen et al.,TGF-beta / beta2-spectrin / CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome.J Clin Invest 126,527-542(2016)。

[0152] 24.J.Chen et al.,Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-beta Pathway.Gastroenterology 154,195-210(2018)。

[0153] 25.M.A.De Matteis,J.S.Morrow,Spectrin tethers and mesh in the biosynthetic pathway.J Cell Sci 113(Pt 13),2331-2343(2000)。

[0154] 26.V.Bennett,D.N.Lorenzo,Spectrin- and ankyrin-based membrane domains and the evolution of vertebrates.Curr Top Membr 72,1-37(2013)。

[0155] 27.H.J.Baek et al.,Caspase-3 / 7-mediated Cleavage of beta2-spectrin is Required for Acetaminophen-induced Liver Damage.Int J Biol Sci 12,172-183(2016)。

[0156] 28.A.Korkut et al.,A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-beta Superfamily.Cell Syst 7,422-437 e427(2018)。

[0157] 29.J.Gutierrez-Cuevas et al.,Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.Cardiovasc Drugs Ther,(2020)。

[0158] 30.A.Sandoval-Rodriguez et al.,Pirfenidone Is an Agonistic Ligand for PPARalpha and Improves NASH by Activation of SIRT1 / LKB1 / pAMPK.Hepatol Commun 4,434-449(2020)。

[0159] 31.M.P.Valdecantos et al.,A novel glucagon-like peptide 1 / glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.Hepatology 65,950-968(2017)。

[0160] 32.M.I.Lefterova et al.,PPARgamma and C / EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.Genes Dev 22,2941-2952(2008)。

[0161] 33.G.Serviddio et al.,Uncoupling protein-2(UCP2)induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis(NASH)liver to ischaemia-reperfusion injury.Gut 57,957-965(2008)。

[0162] 34.A.Nohturfft,R.A.DeBose-Boyd,S.Scheek,J.L.Goldstein,M.S.Brown,Sterols regulate cycling of SREBP cleavage-activating protein(SCAP)between endoplasmic reticulum and Golgi.Proc Natl Acad Sci U S A 96,11235-11240(1999)。

[0163] 35.R.Bertolio et al.,Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism.Nat Commun 10,1326(2019)。

[0164] 36.M.S.Brown,J.L.Goldstein,A proteolytic pathway that controls the cholesterol content of membranes,cells,and blood.Proc Natl Acad Sci U S A 96,11041-11048(1999)。

[0165] 37.B.Knebel et al.,Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass.PLoS One 7,e31812(2012)。

[0166] 38.D.Kozakov et al.,The ClusPro web server for protein-protein docking.Nature protocols 12,255(2017)。

[0167] 39.D.Kozakov,R.Brenke,S.R.Comeau,S.Vajda,PIPER:an FFT‐based protein docking program with pairwise potentials.Proteins:Structure,Function,and Bioinformatics 65,392-406(2006)。

[0168] 40.M.Ricchi et al.,Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes.J Gastroenterol Hepatol 24,830-840(2009)。

[0169] 41.T.Urbanik et al.,Down-regulation of CYLD as a trigger for NF-kappaB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.Int J Oncol 38,121-131(2011)。

[0170] 42.K.Tomita et al.,Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice.Gut 55,415-424(2006)。

[0171] 43.F.Wandrer et al.,TNF-Receptor-1 inhibition reduces liver steatosis,hepatocellular injury and fibrosis in NAFLD mice.Cell Death Dis 11,212(2020)。

[0172] 44.L.Calzadilla Bertot,L.A.Adams,The Natural Course of Non-Alcoholic Fatty Liver Disease.Int J Mol Sci 17,(2016)。

[0173] 45.S.Singh et al.,Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol 13,643-654 e641-649;quiz e639-640(2015)。

[0174] 46.B.Hu et al.,Therapeutic siRNA:state of the art.Signal Transduct Target Ther 5,101(2020)。

[0175] 47.T.Kostrzewski et al.,Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease.World J Gastroenterol 23,204-215(2017)。

[0176] 48.T.Kostrzewski et al.,A Microphysiological System for Studying Nonalcoholic Steatohepatitis.Hepatol Commun 4,77-91(2020)。

[0177] 49.D.K.Jiang et al.,Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma.Nat Genet 45,72-75(2013)。

[0178] 50.J.Li et al.,Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis.Onco Targets Ther 9,1721-1734(2016)。

[0179] 51.A.M.Larson et al.,Acetaminophen-induced acute liver failure:results of a United States multicenter,prospective study.Hepatology 42,1364-1372(2005)。

[0180] 52.T.Yang et al.,Crucial step in cholesterol homeostasis:sterols promote binding of SCAP to INSIG-1,a membrane protein that facilitates retention of SREBPs in ER.Cell 110,489-500(2002)。

[0181] 53.L.A.Kelley et al.,The Phyre2 web portal for protein modeling,prediction and analysis.Nat Protoc 10(6),845-858(2015)。

[0182] 54.A.Fiser and A.Sali,ModLoop:automated modeling of loops in protein structures.Bioinformatics 19(18),2500-2501(2003)。

[0183] 55.N.Guex and M.C.Peitsch,SWISS-MODEL and the Swiss-PdbViewer:an environment for comparative protein modeling.Electrophoresis 18(15),2714-2723(1997)。

Claims

1. 1. A pharmaceutical composition for use in the treatment of obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or hepatocellular carcinoma, comprising at least one siRNA molecule that inhibits the expression of SPTBN1.

2. 2. The pharmaceutical composition of claim 1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 comprises 15 to 30 nucleotides.

3. 3. The pharmaceutical composition of claim 2, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 comprises 15 to 20 nucleotides.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 comprises an overhang region of 1 to 6 nucleotides.

5. The pharmaceutical composition according to any one of claims 1 to 3, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 does not contain an overhang region.

6. 2. The pharmaceutical composition of claim 1, wherein at least one of the siRNA molecules that inhibits the expression of SPTBN1 is set forth as SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:

10.

7. 1. A pharmaceutical composition for use in the treatment of obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis or hepatocellular carcinoma, comprising at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibit the expression of SPTBN1 is homologous to at least 10 nucleotides of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:

10.

8. 1. A pharmaceutical composition for use in the treatment of obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis or hepatocellular carcinoma, comprising at least one siRNA molecule that inhibits the expression of SPTBN1, wherein at least one of the siRNA molecules that inhibit the expression of SPTBN1 has at least 90% sequence identity with SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:

10.

9. A pharmaceutical composition according to any one of claims 1 to 8 for use in treating obesity in a subject in need thereof.

10. 10. The pharmaceutical composition of claim 9, wherein said treating obesity comprises reducing the amount of body fat and / or reducing the body weight of a subject.

11. A pharmaceutical composition according to any one of claims 1 to 8 for use in the treatment of non-alcohol-related fatty liver disease.

12. 12. The pharmaceutical composition of claim 11, wherein the treatment of non-alcohol-related fatty liver disease comprises reducing blood triglycerides in a subject.

13. A pharmaceutical composition according to any one of claims 1 to 8 for use in the treatment of non-alcoholic steatohepatitis.

14. 14. The pharmaceutical composition of claim 13, wherein said treating nonalcoholic steatohepatitis comprises reducing blood triglycerides in a subject.

15. A pharmaceutical composition according to any one of claims 1 to 8 for use in the treatment of hepatocellular carcinoma.

16. 16. The pharmaceutical composition of claim 15, wherein the treatment of hepatocellular carcinoma comprises reducing tumor mass in a subject.

17. The pharmaceutical composition of any one of claims 1 to 16, comprising one siRNA molecule that inhibits the expression of SPTBN1.

18. The pharmaceutical composition of any one of claims 1 to 16, comprising two siRNA moieties that inhibit the expression of SPTBN1.

19. The pharmaceutical composition of any one of claims 1 to 16, comprising three siRNA molecules that inhibit the expression of SPTBN1.

20. The pharmaceutical composition of any one of claims 1 to 16, comprising 4 to 10 siRNA molecules that inhibit the expression of SPTBN1.